Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.35 |
| ▸ | MAT2A | P31153 | 1/20 | 0.33 |
| ▸ | STS | P08842 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29943539 | 0.84 | HTR6 (0.40) | HTR6L3MBTL1 | |
| SCHEMBL17097201 | 0.84 | HTR6 (0.40) | HTR6L3MBTL1 | |
| SCHEMBL23330894 | 0.83 | L3MBTL1 (0.43) | HTR6GPR119L3MBTL1 | |
| SCHEMBL23330476 | 0.82 | HTR6 (0.40) | HTR6L3MBTL1STS | |
| SCHEMBL16727066 | 0.81 | L3MBTL1 (0.46) | MAP2K4HTR6GPR119L3MBTL1MAPT | |
| SCHEMBL31370660 | 0.81 | HTR6 (0.40) | HTR6L3MBTL1MAPTSTSCNR2 | |
| SCHEMBL124286 | 0.80 | HDAC2 (0.41) | HTR6L3MBTL1HDAC1 | |
| SCHEMBL15566143 | 0.80 | L3MBTL1 (0.40) | MAP2K4HTR6GPR119L3MBTL1 | |
| SCHEMBL29364313 | 0.79 | L3MBTL1 (0.41) | HTR6GPR119L3MBTL1 | |
| SCHEMBL29208424 | 0.79 | GPR119 (0.40) | HTR6GPR119L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
| EP-4053124-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2022-09-07 | — | — | EP | disclosed |
| WO-2021083060-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | 中国科学院上海药物研究所 | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | MAP2K4 4086/4885HTR6 3245/4885GPR119 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.